Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma

Annals of Oncology

Volumn 9, Issue 5, 1998, Pages 527-534

  Tobinai, K ^a   Kobayashi, Y ^a   Narabayashi, M ^a   Ogura, M ^b   Kagami, Y ^b   Morishima, Y ^b   Ohtsu, T ^c   Igarashi, T ^c   Sasaki, Y ^c   Kinoshita, T ^d   Murate, T ^d  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^d NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CD20; Chimeric IDEC C2B8; Feasibility study; Lymphoma; Monoclonal antibody; Pharmacokinetics

Indexed keywords

CD20 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C2B8; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ANTIGEN RECOGNITION; ARTICLE; ASTHENIA; B CELL LYMPHOMA; BLOOD TOXICITY; CHILL; CHIMERA; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DYSPNEA; FEMALE; FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PRURITUS; RELAPSE;

EID: 7144250528     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008265313133     Document Type: Article

References (31)

1. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993; 20 (Suppl 5): 75-88.
2. Bierman PJ, Vose JM, Anderson JR et al. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 445-50.
3. Meeker TC, Lowder J, Maloney DG et al. A clinical trial of antiidiotype therapy for B cell malignancy. Blood 1985; 65: 1349-63.
4. Stashenko P, Nadler LM, Hardy R et al. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980; 125: 1678-85.
5. Tobinai K, Hirose M, Yamada H et al. Cellular origin of human lymphoid malignancies as based on immunologic analysis of membrane differentiation antigens. Jpn J Clin Oncol 1982; 12: 73-90.
6. Anderson KC, Bates MP, Slaughenhoupt BL et al. Expression of human B cell associated antigens on leukemias and lymphomas: A model of human B cell differentiation. Blood 1984; 63: 1424-33.
7. Press OW, Appelbaum F, Ledbetter JA et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 1987; 69: 584-91.
8. Press OW, Eary JF, Appelbaum FR et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993; 329: 459-65.
9. Press OW, Eary JF, Appelbaum FR et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 1995; 346: 336-40.
10. 131I] anti-B1 (anti-CD20) antibody. N Engl J Med 1993; 329: 459-65.
11. Kaminski MS, Zasadny KR, Francis IR et al. Iodine-131: Anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996; 14: 1974-81.
12. Knox SJ, Goris ML, Trisler K et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996; 2: 457-70.
13. Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vitro by chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-45.
14. Maloney DG, Liles TM, Czerwinski DK et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84: 2457-66.
15. Maloney DG, Grillo-Lopez AJ, Bodkin D et al. Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 3266-74.
16. Maloney DG, Grillo-Lopez AJ, White CA et al. IDEC-C2B8 (rituximab) anti-CD20 antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-95.
17. McLaughlin P, Cabanillas F, Grillo-Lopez, AJ et al. IDEC-C2B8 anti-CD20 antibody: final report on a phase III pivotal trial in patients with relapsed low-grade or follicular lymphoma. Blood 1996; 88 (Suppl 1): 90a (Abstr).
18. Mason DY, Comans-Bitter W, Cordell JL et al. Antibody L26 recognizes an intracellular epitope on the B-cell-associated CD20 antigen. Am J Pathol 1990; 136: 1215-22.
19. Tobinai K, Kohno A, Shimada Y et al. Toxicity grading criteria of the Japan Clinical Oncology Group. Jpn J Clin Oncol 1993; 23: 250-7.
20. Tada M, Hinuma S, Abo T et al. Murine antibody-dependent cell-mediated cytoloxicity: Failure to detect effector cells equivalent to human K cells. J Immunol 1980; 124: 1929-36.
21. Oshimi K, Gonda N, Sumiya M et al. Effects of corticosteroids on natural killer cell activity in systemic lupus erythematosus. Clin Exp Immunol 1980; 40: 83-88.
22. WHO Handbook for Reporting Results of Cancer Treatment. Geneva: WHO 1979.
23. Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a Working Formulation for clinical usage. Cancer 1982; 49: 2112-35.
24. Demidem A, Lam T, Alas S et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997; 12: 177-86.
25. Maloney DG, Smith B, Appelbaum FR. The anti-tumor effect of monoclonal anti-CD20 antibody therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma cell lines. Blood 1996; 88: 637a (Abstr).
26. Rosenberg J, Waldichuk C, Grillo-Lopez AJ et al. Pharmacokinetic analysis of serum concentrations of the chimeric anti-CD20 antibody IDEC-C2B8 in patients with relapsed B-cell lymphoma. Proc Am Soc Clin Oncol 1996; 15: 418 (Abstr).
27. Berinstein N, White CA, Grillo-Lopez AJ et al. IDEC-C2B8 (rituximab) levels correlate with response in low-grade or follicular non-Hodgkin's lymphoma. Proc Am Assoc Cancer Res 1997; 38: 85 (Abstr).
28. Kadin ME, Berard CW, Nanba K et al. Lymphoproliferative diseases in Japan and western countries. Hum Pathol 1983; 14: 745-72.
29. Ohsawa M, Aozasa K, Tsujimura T et al. Non-Hodgkin's lymphoma of follicular center cell type in Osaka, Japan. Eur J Cancer Clin Oncol 1989; 25: 1875-8.
30. Katsumata N, Matsuno Y, Nakayama H et al. Prognostic factors and a predictive model of follicular lymphoma: A 25-year study at a single institution in Japan. Jpn J Clin Oncol 1996; 26: 445-54.
31. Yanagihara ET, Blaisdel RK, Hayashi T et al. Malignant lymphoma in Hawaii-Japanese: A retrospective morphologic survey. Hematol Oncol 1989; 7: 219-32.